Inovio Pharma (INO) Misses Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Inovio Pharmaceuticals Reports 2014 Fourth Quarter and Year End Financial Results
March 16, 2015 6:30 AM EDTPLYMOUTH MEETING, Pa., March 16, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (Nasdaq: INO) today reported financial results for the fourth quarter and year ended December 31, 2014.
Total revenue was $2.5 million and $10.5 million for the quarter and year ended December 31, 2014, as compared to $1.7 million and $13.5 million for the same periods in 2013.
Total operating expenses for the quarter and year ended December 31, 2014, were $13.5 million and $50.0 million as compared to $9.7 million and $33.0 million for the same periods in 2013.
The net loss attributable to common stockholders for the quarter and year ended December 31, 2014, was $7.4 million, or $0.12 per... More
Inovio Pharmaceuticals Reports 2014 Fourth Quarter and Year End Financial Results
March 16, 2015 6:30 AM EDTPLYMOUTH MEETING, Pa., March 16, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (Nasdaq: INO) today reported financial results for the fourth quarter and year ended December 31, 2014.
Total revenue was $2.5 million and $10.5 million for the quarter and year ended December 31, 2014, as compared to $1.7 million and $13.5 million for the same periods in 2013.
Total operating expenses for the quarter and year ended December 31, 2014, were $13.5 million and $50.0 million as compared to $9.7 million and $33.0 million for the same periods in 2013.
The net loss attributable to common stockholders for the quarter and year ended December 31, 2014, was $7.4 million, or $0.12 per... More
